Insider Selling: Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) CFO Sells 1,775 Shares of Stock

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) CFO Sandip Kapadia sold 1,775 shares of the company’s stock in a transaction on Monday, January 27th. The shares were sold at an average price of $38.05, for a total transaction of $67,538.75. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Sandip Kapadia also recently made the following trade(s):

• On Tuesday, January 21st, Sandip Kapadia sold 25,000 shares of Harmony Biosciences stock. The stock was sold at an average price of $40.18, for a total value of $1,004,500.00.

Harmony Biosciences Trading Up 0.4 %

Shares of NASDAQ:HRMY opened at $38.42 on Wednesday. The firm has a market cap of $2.19 billion, a price-to-earnings ratio of 18.21, a PEG ratio of 0.51 and a beta of 0.78. Harmony Biosciences Holdings, Inc. has a 12 month low of $28.14 and a 12 month high of $41.61. The company’s fifty day simple moving average is $35.08 and its 200 day simple moving average is $35.19. The company has a quick ratio of 3.20, a current ratio of 3.24 and a debt-to-equity ratio of 0.28.

Harmony Biosciences (NASDAQ:HRMY) last released its quarterly earnings results on Tuesday, October 29th. The company reported $0.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.15. The firm had revenue of $186.00 million for the quarter, compared to the consensus estimate of $184.07 million. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The company’s revenue for the quarter was up 16.0% on a year-over-year basis. During the same quarter last year, the business posted $0.63 EPS. As a group, research analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current fiscal year.

Institutional Investors Weigh In On Harmony Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Pacer Advisors Inc. boosted its position in Harmony Biosciences by 18.2% during the 4th quarter. Pacer Advisors Inc. now owns 2,279,918 shares of the company’s stock worth $78,452,000 after acquiring an additional 351,582 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Harmony Biosciences by 13.3% in the second quarter. Dimensional Fund Advisors LP now owns 956,785 shares of the company’s stock worth $28,871,000 after purchasing an additional 112,197 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in Harmony Biosciences by 27.1% during the third quarter. Massachusetts Financial Services Co. MA now owns 660,391 shares of the company’s stock worth $26,416,000 after purchasing an additional 140,690 shares during the last quarter. Millennium Management LLC grew its position in Harmony Biosciences by 51.6% in the second quarter. Millennium Management LLC now owns 307,420 shares of the company’s stock valued at $9,275,000 after purchasing an additional 104,691 shares in the last quarter. Finally, Marshall Wace LLP increased its stake in Harmony Biosciences by 145.4% in the 2nd quarter. Marshall Wace LLP now owns 305,612 shares of the company’s stock valued at $9,220,000 after buying an additional 181,092 shares during the last quarter. Institutional investors and hedge funds own 86.23% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on HRMY shares. Oppenheimer restated an “outperform” rating and set a $59.00 target price (up previously from $56.00) on shares of Harmony Biosciences in a report on Wednesday, October 30th. Needham & Company LLC reaffirmed a “buy” rating and issued a $52.00 target price on shares of Harmony Biosciences in a research note on Monday, January 13th. HC Wainwright reissued a “buy” rating and set a $75.00 price target on shares of Harmony Biosciences in a research report on Monday. Raymond James restated an “outperform” rating and issued a $40.00 price objective on shares of Harmony Biosciences in a research report on Thursday, October 10th. Finally, Cantor Fitzgerald lifted their target price on Harmony Biosciences from $51.00 to $58.00 and gave the stock an “overweight” rating in a report on Wednesday, October 30th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $55.00.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.